Jazz Pharmaceuticals Director Bruce C. Cozadd Sells $1.5M in Shares via 10b5-1 Plan

Insider Transaction Overview

On September 1, 2026, Bruce C. Cozadd, Director at Jazz Pharmaceuticals plc ($JAZZ), executed an open-market sale of 6,000 Ordinary Shares at an average price of $250.13 per share, for aggregate gross proceeds of approximately $1,500,780.

Additionally, on August 31, 2026, two tax withholding transactions (Code F) totaling 1,219 shares were executed at prices of $244.064 and $241.3899 per share to satisfy tax obligations upon the vesting of restricted stock units.

Key Highlights

• Pre-Arranged 10b5-1 Plan: The sale of 6,000 shares was conducted pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2025.
• Remaining Position: Following these transactions, Mr. Cozadd directly holds 351,875 Ordinary Shares.
• Significance: Low. The open-market disposition represents less than 2% of his total equity holdings and was executed through a pre-established 10b5-1 plan.